View in EDS

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

Saved in:
Bibliographic Details
Title: Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Authors: Lindemann, K.1 stinalindemann@hotmail.com, Kristensen, G.2, Mirza, M. R.3, Davies, L.4, Hilpert, F.5, Romero, I.6, Ayhan, A.7, Burges, A.8, Rubio, M. J.9, Raspagliesi, F.10, Huizing, M.11, Creemers, G.-J.12, Lykka, M.13, Lee, C. K.4, Gebski, V.4, Pujade-Lauraine, E.14
Source: Annals of Oncology. Aug2016, Vol. 27 Issue 8, p1505-1510. 6p. 1 Diagram, 2 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdw238